Equity Profile

VRTX

VERTEX PHARMACEUTICA

Health CareBiotechnology$113.4B

May4Mon

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Vertex Pharmaceuticals Beats on EPS, Stock Up 1.4%

Metric	Actual	Expected	Surprise
EPS	$4.47	$4.29	+21.20%
Revenue	N/A	$3.0B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Vertex Pharmaceuticals Beats on EPS, Stock Up 1.4%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$4.47	$4.29	+21.20%
Revenue	N/A	$3.0B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, so the analysis is based solely on numerical results.

What It Means

Vertex Pharmaceuticals reported strong earnings with an EPS that exceeded expectations significantly, leading to a 1.4% increase in stock price. However, revenue figures were not disclosed, leaving some uncertainty. Investors may view the EPS beat positively, but the lack of revenue details and guidance could temper enthusiasm.

Company Snapshot

Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases. With a market cap of $108 billion, it plays a significant role in the health care sector, particularly in the treatment of cystic fibrosis and other genetic disorders.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$4.29

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$3.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.42%

Avg Stock Reaction

+0.86%

Last Quarter Recap

In the last quarter (Q4-2025), Vertex reported an EPS of $5.03, exceeding estimates by 14.21%. The stock reacted positively, gaining 0.82% the following day.

Management Promises & Guidance

Continued focus on expanding its pipeline of therapies.
Commitment to maintaining strong sales in existing products.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Analysts expect Vertex to report strong earnings, with a consensus EPS of $4.29 and revenue of $3.0 billion. The company has a history of beating earnings expectations, which adds to investor optimism.

Bull Case

If Vertex exceeds EPS and revenue estimates, it could signal robust demand for its products and a strong pipeline, leading to a positive stock reaction.

Bear Case

If the company misses expectations or provides weak guidance, it could raise concerns about future growth and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$4.29

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$3.0B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $4.29 as expected?

A strong EPS could reinforce investor confidence in Vertex's profitability and growth potential.

What guidance will management provide for future revenue?

Guidance on revenue will be crucial for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vertex to exceed its earnings expectations due to strong sales in its existing therapies.

Supporting Evidence

Vertex has consistently beaten EPS estimates in recent quarters, suggesting a trend of strong performance.

The options market is pricing a 6.07% move, indicating expectations for volatility that may not align with the company's historical stability.

Key Risk

If revenue growth exceeds $3.2 billion, it could challenge the current consensus and shift investor sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Vertex's ability to maintain its growth momentum amidst competitive pressures and market dynamics.

Bull Confirmed If

An EPS of $4.50 or higher would confirm the bull case by showcasing strong earnings growth.

Bear Confirmed If

An EPS below $4.00 would confirm the bear case, indicating potential issues in performance.

Pre-Earnings Positioning

Options Market

Implied Move

±6.07%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±6.1% while VRTX has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

23.2%

Calls (65K)P/C Ratio: 2.15Puts (161K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vertex beats expectations, history suggests the stock could rise by around 0.54%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

If Vertex misses expectations, history suggests a potential decline of around 2.03%, raising concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the sales performance of existing therapies.
2Any new developments in the product pipeline.
3Management's outlook on market conditions and competition.
4Details on research and development initiatives.
5Guidance for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$4.29

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$3.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.42%

Avg Stock Reaction

+0.86%

Last Quarter Recap

In the last quarter (Q4-2025), Vertex reported an EPS of $5.03, exceeding estimates by 14.21%. The stock reacted positively, gaining 0.82% the following day.

Management Promises & Guidance

Continued focus on expanding its pipeline of therapies.
Commitment to maintaining strong sales in existing products.
Plans to enhance research and development efforts.

Expectations

Wall Street Expectations

Bull Case

If Vertex exceeds EPS and revenue estimates, it could signal robust demand for its products and a strong pipeline, leading to a positive stock reaction.

Bear Case

If the company misses expectations or provides weak guidance, it could raise concerns about future growth and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$4.29

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$3.0B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $4.29 as expected?

A strong EPS could reinforce investor confidence in Vertex's profitability and growth potential.

What guidance will management provide for future revenue?

Guidance on revenue will be crucial for assessing the company's growth trajectory and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vertex to exceed its earnings expectations due to strong sales in its existing therapies.

Supporting Evidence

Vertex has consistently beaten EPS estimates in recent quarters, suggesting a trend of strong performance.

The options market is pricing a 6.07% move, indicating expectations for volatility that may not align with the company's historical stability.

Key Risk

If revenue growth exceeds $3.2 billion, it could challenge the current consensus and shift investor sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Vertex's ability to maintain its growth momentum amidst competitive pressures and market dynamics.

Bull Confirmed If

An EPS of $4.50 or higher would confirm the bull case by showcasing strong earnings growth.

Bear Confirmed If

An EPS below $4.00 would confirm the bear case, indicating potential issues in performance.

Pre-Earnings Positioning

Options Market

Implied Move

±6.07%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.

Options are pricing ±6.1% while VRTX has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

23.2%

Calls (65K)P/C Ratio: 2.15Puts (161K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vertex beats expectations, history suggests the stock could rise by around 0.54%, confirming strong demand for its products.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

If Vertex misses expectations, history suggests a potential decline of around 2.03%, raising concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the sales performance of existing therapies.
2Any new developments in the product pipeline.
3Management's outlook on market conditions and competition.
4Details on research and development initiatives.
5Guidance for the upcoming quarters.